ARS Pharmaceuticals Founder-CEO and CMO Both Terminated Within Nine Days
Management crisis
Company Background
ARS Pharmaceuticals (Nasdaq: SPRY, ~$740M market cap) is a San Diego-based biopharmaceutical company that began commercializing neffy — an epinephrine nasal spray and the first needle-free FDA-approved emergency treatment for Type I allergic reactions, including anaphylaxis — in late 2024. Its first full year of U.S. sales produced $72.2 million in net product revenue, while selling, general, and administrative expenses reached $230.1 million as the company invested heavily in direct-to-consumer advertising and sales force expansion. Net loss for full-year 2025 was $171.3 million. First-quarter 2026 U.S. product revenue was $17.5 million, with a net loss of $60.6 million. As of March 31, 2026, the company held $201.0 million in cash, cash equivalents, and short-term investments, which management stated is sufficient to fund operations through expected cash-flow break-even.
The company has been pursuing several growth initiatives simultaneously: expanding its sales force from 106 to 148 representatives, negotiating unrestricted formulary access with remaining major pharmacy benefit managers including CVS Caremark, expanding internationally following European Commission approval of EURneffy in March 2026 and Health Canada approval in April 2026, and running a Phase 2b clinical trial in chronic spontaneous urticaria with an interim data readout expected in the fourth quarter of 2026. In August 2025, generics maker Lupin filed an abbreviated new drug application for a generic version of neffy 2 mg, which ARS said it would contest with a patent infringement suit seeking a 30-month regulatory stay.
What Was Disclosed
Richard Lowenthal, the company's co-founder and longtime chief executive, was notified on July 6, 2026 that his employment was being terminated without cause, effective immediately. The following day, the board appointed Donn Casale — who had joined as President on June 1, 2026 — as the new CEO and as a Class III director to serve until the 2029 annual meeting. Then, on July 15, 2026, Chief Medical Officer Sarina Tanimoto, M.D. ceased employment under conditions constituting a termination without cause. On the same date, Lowenthal resigned from the board, a step his employment agreement required as a condition of receiving his severance compensation.
Beyond the standard severance benefits set out in the company's Definitive Proxy Statement filed April 29, 2026, the company agreed to pay Lowenthal an additional one-time payment of $217,350 and Tanimoto an additional one-time payment of $111,780, each representing a prorated amount of their respective 2026 target bonuses. Both the additional payments and the previously described severance benefits are conditioned on the effectiveness of a release of claims that each executive must provide to the company. The filing does not provide any stated reason for either termination beyond the without-cause classification.
Why It Matters
The two departures remove the most senior figures who guided neffy from development through FDA approval and into commercial launch. Lowenthal had been the voice of every quarterly earnings call through May 2026 and was co-author of the company's commercial and clinical strategy. Tanimoto co-authored the company's key real-world evidence publication on neffy's effectiveness — data the company cited in investor presentations as a driver of prescriber confidence — and was the named medical officer overseeing the Phase 2b CSU trial, for which interim results are now expected in Q4 2026 under new leadership. No replacement CMO has been announced.
Casale took on the President role only on June 1, 2026, giving him approximately six weeks at the company before being named CEO on July 7. He had not yet led a public earnings call or reported quarterly results before inheriting the top job. The company is simultaneously navigating a pending CVS Caremark formulary decision that was described in the May 2026 earnings release as being in the final stages of approval — an access milestone management called central to second-half revenue growth. Whether the leadership transition creates any friction on that or other commercial priorities is not addressed in the filing.
The release-of-claims condition on both the standard and supplemental severance payments is a standard feature of executive separations and does not on its own indicate any particular controversy. What is less routine is losing both the founding CEO and the CMO within nine days during the commercial launch of a company's sole product, with a clinical readout and a major coverage decision pending in the same quarter.